Compare LAES & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | OVID |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.5M | 522.6M |
| IPO Year | 2022 | 2017 |
| Metric | LAES | OVID |
|---|---|---|
| Price | $3.13 | $2.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $4.60 |
| AVG Volume (30 Days) | ★ 19.1M | 2.4M |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | $19.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.99 | $0.30 |
| 52 Week High | $8.71 | $3.11 |
| Indicator | LAES | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 55.36 |
| Support Level | $2.94 | $2.56 |
| Resistance Level | $3.38 | $2.74 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 28.95 | 90.87 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.